Results 261 to 270 of about 927,717 (352)

Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real‐World Databases from Korea and Taiwan

Clinical Pharmacology &Therapeutics, EarlyView.
With the increasing volume of clinical evidence derived from large‐scale Asian real‐world data (RWD) and the growing interest in its use in regulatory decision‐making, it is important to conduct benchmarking exercises that evaluate whether studies using Asian RWD can generate similar conclusions as randomized controlled trials (RCTs).
Hwa Yeon Ko, Philip C. M. Au, Michael Chun‐Yuan Cheng, Ching‐Lung Cheung, Ahhyung Choi, Miyuki Hsing‐Chun Hsieh, Han Eol Jeong, Edward Chia‐Cheng Lai, Brian Meng‐Hsun Li, Kenneth K. C. Man, Jeremy A. Rassen, Daniel Hsiang‐Te Tsai, Shirley V. Wang, Ian C. K. Wong, Ju‐Young Shin, Sohee Park   +15 more
wiley   +1 more source

Global burden and trend of rheumatic heart disease among women of childbearing age, 1990-2021, with projection to 2040. [PDF]

BMC Cardiovasc Disord
Chen Y, Deng B, Nie Y, Xian W, Li Y, Yang S.   +5 more
europepmc   +1 more source

Clinical features of rheumatic heart disease in Bangladesh.

, 1984
Shumpei Okubo, Seiki Nagata, Yoshikazu Masuda, Kohei Kawazoe, M Atobe, Hisao Manabe   +5 more
openalex   +2 more sources

Nonsteroidal Anti‐Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are widely used for pain and inflammation but are associated with gastrointestinal (GI) bleeding. While this risk is well established, most studies evaluate NSAIDs as a homogenous class, limiting clinical decision‐making based on individual agent safety.
Abdelrahman G. Tawfik, Ainhoa Gomez‐Lumbreras, Guilherme Del Fiol, Kensaku Kawamoto, Katy E. Trinkley, Thomas Reese, Aubrey Jones, Daniel C. Malone   +7 more
wiley   +1 more source

Massive cardiomegaly secondary to rheumatic heart disease. [PDF]

Pan Afr Med J
Aurangabadkar G, Choudhary S.
europepmc   +1 more source

ASO, ASK and ADNase-B values in rheumatic fever, rheumatic heart disease and other infections by hemolytic streptococcus.

, 1980
Nobuo Watanabe, Akira Arimura, MUNEMITSU KOBAYASHI, Masahiro Oshima   +3 more
openalex   +2 more sources

Pharmacomicrobiomics

Clinical Pharmacology &Therapeutics, EarlyView.
Oral medications encounter gut commensal microbes that participate directly and indirectly in drug effects through metabolism, interactions with drug metabolites, or production of substrates that compete with drugs for drug‐metabolizing enzymes, consequently influencing drug pharmacokinetics.
Naomi Gronich, Naama Geva‐Zatorsky, Rachel Herren, Libusha Kelly, Ziv Cohen, Haiying Zhou, Yi‐Ching Chen, Khalid Shah, Talin A. Robinson‐Catala, Grecia Frisby, Jason H. Karnes, Lisl Shoda   +11 more
wiley   +1 more source

Advanced Chronic Rheumatic Heart Disease Associated With Substantial Myocardial and Valvular Fibrosis on Cardiovascular Magnetic Resonance. [PDF]

Cureus
Aremu OO, Samuels P, Jermy S, Lumngwena EN, Mutithu DW, Familusi M, Herbert E, Speelman A, Skatulla S, Ntusi NA.   +9 more
europepmc   +1 more source

Antibody titer to group A streptococcal polysaccharide in rheumatic fever and rheumatic heart disease.

, 1987
Satoshi Fujikawa, Masahiko Ohkuni, Hung‐Chi Lue   +2 more
openalex   +2 more sources

Evolving Real‐World Data and Evidence Use for New Drugs and Regenerative Medical Products Approvals in Japan—An Analysis of the 6‐Year Trend

Clinical Pharmacology &Therapeutics, EarlyView.
Several regulatory initiatives have been made to clarify the acceptability and requirements of real‐world data and real‐world evidence (RWD/E) for the benefit/risk assessment of new medical products in Japan. The objectives of this review were to characterize the use of RWD/E in regulatory applications of new medical products and to describe the ...
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source